LivaNova PLC (NASDAQ:LIVN) Short Interest Update

LivaNova PLC (NASDAQ:LIVN) was the recipient of a large decline in short interest in February. As of February 13th, there was short interest totaling 2,032,704 shares, a decline of 16.6% from the January 29th total of 2,436,767 shares. Based on an average daily volume of 676,965 shares, the short-interest ratio is presently 3.0 days. Approximately 3.7% of the company’s shares are sold short. Approximately 3.7% of the company’s shares are sold short. Based on an average daily volume of 676,965 shares, the short-interest ratio is presently 3.0 days.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on LIVN shares. Barclays upped their target price on LivaNova from $67.00 to $73.00 and gave the company an “equal weight” rating in a report on Friday. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $66.00 price objective on shares of LivaNova in a research report on Friday, January 9th. Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a research report on Monday, December 29th. Piper Sandler reissued an “overweight” rating and set a $85.00 target price on shares of LivaNova in a research note on Thursday, February 19th. Finally, Needham & Company LLC upped their price target on shares of LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $74.78.

Institutional Investors Weigh In On LivaNova

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Pacer Advisors Inc. raised its stake in LivaNova by 131.7% during the 4th quarter. Pacer Advisors Inc. now owns 16,661 shares of the company’s stock valued at $1,025,000 after purchasing an additional 9,471 shares during the last quarter. Invesco Ltd. increased its holdings in shares of LivaNova by 4.5% during the 4th quarter. Invesco Ltd. now owns 1,091,086 shares of the company’s stock worth $67,135,000 after purchasing an additional 47,323 shares during the period. Corient Private Wealth LLC bought a new position in shares of LivaNova during the 4th quarter worth about $604,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of LivaNova during the fourth quarter valued at about $306,000. Finally, State of Tennessee Department of Treasury grew its position in LivaNova by 44.9% during the fourth quarter. State of Tennessee Department of Treasury now owns 30,304 shares of the company’s stock worth $1,991,000 after buying an additional 9,396 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Stock Performance

LIVN stock opened at $70.27 on Tuesday. The firm has a 50 day moving average of $64.89 and a two-hundred day moving average of $59.26. LivaNova has a 12 month low of $32.48 and a 12 month high of $71.92. The company has a market capitalization of $3.84 billion, a price-to-earnings ratio of -15.76 and a beta of 0.92. The company has a quick ratio of 1.16, a current ratio of 1.36 and a debt-to-equity ratio of 0.29.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.80 by $0.06. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The company had revenue of $360.86 million during the quarter, compared to the consensus estimate of $354.31 million. During the same quarter in the prior year, the company posted $0.81 EPS. The firm’s revenue was up 12.2% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. As a group, equities analysts anticipate that LivaNova will post 2.85 EPS for the current fiscal year.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.